Loading...
Market
What will be the market share of FluMist nasal spray in the 2024-2025 flu season?
2
Resolution / Starting Odds
Less than 5% • 25%
5% to 10% • 25%
10% to 20% • 25%
More than 20% • 25%
Public health reports and surveys from CDC and other health organizations
Story
FDA Approves FluMist Nasal Spray, First Self-Administered Flu Vaccine
Sep 20, 2024, 08:01 PM
The U.S. Food and Drug Administration (FDA) has approved AstraZeneca's FluMist nasal spray influenza vaccine for self- or caregiver-administration. This approval, announced on Friday, marks the first time a self-administered flu vaccine can be administered without the need for a healthcare provider. FluMist is licensed for individuals aged 2 to 49 and will be available for at-home use starting next flu season. Patients will need to complete a screening and eligibility assessment through a third-party pharmacy before obtaining the vaccine. The FDA's decision is part of its broader effort to expand consumer access to medicines and reduce healthcare costs and barriers, providing an alternative to flu shots.
View original story
Similar markets
Less than 5% • 25%
5-10% • 25%
10-20% • 25%
More than 20% • 25%
Less than 10% • 25%
10% - 20% • 25%
20% - 30% • 25%
More than 30% • 25%
Yes • 50%
No • 50%
1 to 2 million • 25%
Less than 1 million • 25%
2 to 3 million • 25%
More than 3 million • 25%
Pharmacies • 25%
Online retailers • 25%
Healthcare providers • 25%
Other • 25%
Yes • 50%
No • 50%
Less than 500,000 • 25%
500,000 to 1 million • 25%
1 million to 2 million • 25%
More than 2 million • 25%
Pharmacies • 25%
Online retailers • 25%
Healthcare providers • 25%
Other • 25%
